A Placebo Controlled Trial of Acebilustat (CTX 4430) for the Treatment of Human Upper Extremity Lymphedema

Summary

This study is designed to investigate the response of unilateral upper extremity (arm) lymphedema, during pharmacologic treatment of lymphedema with oral placebo and oral acebilustat. Participants will receive "study drug" (Acebilustat or placebo), for 9 months. For 3 of these months, the participant will receive placebo; for 6 of these months, the participant will receive active ingredient, acebilustat. The study is blinded which means that the participant will not be told which study pill they are taking.

Timeline

Start

2022-07-27

Primary completion

2025-10-21

Completion

2025-12-01

Drugs

Indications